Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?GuruFocus · Oct 12, 2026
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PRNewsWire · Oct 12, 2026
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRXBusiness Wire · Oct 12, 2026
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)GuruFocus · Oct 11, 2026
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)PRNewsWire · Oct 11, 2026
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioZacks Investment Research · Oct 9, 2026Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | $0.65 | $0.73 | Beat |
| Apr 30, 2026 | $0.61 | $0.60 | Miss |
| Feb 26, 2026 | $0.85 | $0.57 | Miss |
| Nov 6, 2025 | $0.65 | $0.70 | Beat |
| Aug 5, 2025 | $0.72 | $0.74 | Beat |
| May 8, 2025 | $0.57 | $0.62 | Beat |